Yuri Weigel

Special Counsel
Full contact info

I love helping great people build great businesses.

Experience

Parse Biosciences Closes $50 Million Series C

December 14, 2023

Cooley advised Parse Biosciences on its $50 million Series C financing. Partner Sonya Erickson led the Cooley team advising Parse Biosciences, which develops single-cell sequencing products used by more than 1,000 labs worldwide.

Read more

Related contacts

Sonya Erickson
Partner and Business Department Chair, Seattle
Lucy Bauer
Associate, Seattle
Willy Cowles
Associate, Seattle
Yuri Weigel
Special Counsel, Seattle
Scott Lin
Associate, San Francisco
Colleen Badgley
Partner, Seattle

Related Practices & Industries

Rodeo Therapeutics Agrees to Sell to Amgen for $721 Million

March 31, 2021

Cooley advised Rodeo Therapeutics, a biopharmaceutical company that develops small molecule therapies, on its agreement to sell to Amgen, a leader in biotechnology-based human therapeutics, for $721 million. Partner Laura Medina led the Cooley team advising Rodeo. 

Read more

Related contacts

Meredith Klionsky
Associate, Washington, DC
Laura M. Medina
Partner, Colorado
Ajay Athavale
Associate, San Francisco
Willy Cowles
Associate, Seattle
Alexander Ellebracht
Associate, Palo Alto
Charity Williams
Partner, San Diego
Yuri Weigel
Special Counsel, Seattle
Sonya Erickson
Partner and Business Department Chair, Seattle
Jon Cousin
Partner, Washington, DC
Patrick Sharma
Associate, Los Angeles Santa Monica
Mark Windfeld-Hansen
Senior Counsel, Palo Alto

Related Practices & Industries

ConvergeOne Announces $1.2 Billion Combination With Forum Merger to Become Public Company

February 23, 2018

Cooley advised leading global IT services provider ConvergeOne on its agreement to combine with Forum Merger Corporation, allowing ConvergeOne to become a public company, with an anticipated initial enterprise value of approximately $1.2 billion. Cooley partners Mehdi Khodadad and John McKenna led the team advising ConvergeOne.

Read more

Related contacts

John McKenna
Partner, Palo Alto
Alan Hambelton
Partner, Seattle
Colleen Badgley
Partner, Seattle
Yuri Weigel
Special Counsel, Seattle
Lois Voelz
Senior Counsel, Palo Alto
Peter Burns
Of Counsel, Palo Alto
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Jacqueline Grise
Partner, Washington, DC
Sharon Connaughton
Special Counsel, Washington, DC
Barbara Mirza
Partner, Los Angeles Santa Monica
Stephanie Gentile
Partner, New York
Brian Woodard
Paralegal Specialist, Seattle

Related Practices & Industries

Alder Biopharmaceuticals $80 Million Initial Public Offering

May 14, 2014

Seattle – Cooley advised Alder Biopharmaceuticals on its $80 million initial public offering. Alder is a Washington-based clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder is currently developing two lead product candidates: ALD403, an investigational monoclonal antibody for migraine, and Clazakizumab, an investigational monoclonal antibody for rheumatoid arthritis and other autoimmune indications, in collaboration with Bristol-Myers Squibb. The company now trades on the Nasdaq Global Stock Market under the symbol "ALDR."

Related contacts

Sonya Erickson
Partner and Business Department Chair, Seattle
John McKenna
Partner, Palo Alto
Alan Hambelton
Partner, Seattle
Yuri Weigel
Special Counsel, Seattle
Natasha Leskovsek
Of Counsel, Washington, DC
Marya Postner
Partner, Palo Alto
Mark Windfeld-Hansen
Senior Counsel, Palo Alto

Related Practices & Industries